{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:09:35Z","timestamp":1794892175353,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymgme.2025.109110","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:13:39Z","timestamp":1745262819000},"page":"109110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review"],"prefix":"10.1016","volume":"145","author":[{"given":"Uma","family":"Ramaswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tylee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genaro","family":"Castillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraraj Umesh","family":"Doobaree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109110_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109110_bb0010","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb\u2083-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2025.109110_bb0020","doi-asserted-by":"crossref","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr. Res. 2008;64(5):550\u20135.","DOI":"10.1203\/PDR.0b013e318183f132"},{"key":"10.1016\/j.ymgme.2025.109110_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/TACG.S146022","article-title":"Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations","volume":"12","author":"Oliveira","year":"2019","journal-title":"Appl. Clin. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2025.109110_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/hgv.2017.2","article-title":"A new mutation found in newborn screening for Fabry disease evaluated by plasma globotriaosylsphingosine levels","volume":"4","author":"Chinen","year":"2017","journal-title":"Hum. Genome Var."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijns9020031","article-title":"Newborn screening for Fabry disease: current status of knowledge","volume":"9","author":"Gragnaniello","year":"2023","journal-title":"Int. J. Neonatal Screen."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","article-title":"Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry","volume":"163","author":"Scott","year":"2013","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109110_bb0060","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109110_bb0065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109110_bb0080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2025.109110_bb0085","author":"US Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2025.109110_bb0090","author":"European Medicines Agency"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109110_bb0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and later-onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109110_bb0125","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2025.109110_bb0130","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2025.109110_bb0135","article-title":"The role of globotriaosylsphingosine (Lyso-Gb3) in the diagnosis and monitoring of fabry disease: a systematic review","author":"Moride","year":"2022","journal-title":"PROSPERO"},{"key":"10.1016\/j.ymgme.2025.109110_bb0140","author":"Joanna Briggs Institute"},{"issue":"i4919","key":"10.1016\/j.ymgme.2025.109110_bb0145","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2025.109110_bb0150","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ymgme.2025.109110_bb0155","author":"BMJ"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109110_bb0160","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109110_bb0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2017.08.004","article-title":"A simple method for quantification of plasma globotriaosylsphingosine: utility for Fabry disease","volume":"122","author":"Talbot","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000277","article-title":"Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen","year":"2018","journal-title":"BMJ Open Respir. Res."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0175","first-page":"3733","article-title":"Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease","volume":"15","author":"Ouyang","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"23","key":"10.1016\/j.ymgme.2025.109110_bb0180","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.3390\/molecules26237358","article-title":"A rapid and simple UHPLC-MS\/MS method for quantification of plasma globotriaosylsphingosine (lyso-Gb3)","volume":"26","author":"Perrone","year":"2021","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.ymgme.2025.109110_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109110_bb0195","first-page":"1","article-title":"Endocrine disorders in patients with Fabry disease: insights from a reference Centre prospective study","author":"Bothou","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.ymgme.2025.109110_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb 3) as a biomarker for cardiac variant (N215S) Fabry disease","volume":"41","author":"Alharbi","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109110_bb0205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2019.10.005","article-title":"The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease","volume":"500","author":"Alharbi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2025.109110_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-galactosidase A p. A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109110_bb0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/joim.13125","article-title":"Stratification of Fabry mutations in clinical practice: a closer look at \u03b1-galactosidase A-3D structure","volume":"288","author":"Rickert","year":"2020","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0877-4","article-title":"Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY","volume":"13","author":"Mauhin","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109110_bb0225","article-title":"Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy","volume":"25","author":"Tsukimura","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109110_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109110_bb0235","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/biom11070951","article-title":"Newborn screening for Fabry disease in northeastern Italy: results of five years of experience","volume":"11","author":"Gragnaniello","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s13023-021-02136-1","article-title":"Multidisciplinary approach to screening and management of children with Fabry disease: practice at a tertiary children\u2019s Hospital in China","volume":"16","author":"Shen","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0245","first-page":"19","article-title":"Neonatal screening for Fabry disease in Brazil: pilot study update","volume":"146","author":"Giugliani","year":"2022","journal-title":"Nephron"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109110_bb0250","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1253\/circj.CJ-19-0110","article-title":"Plasma globotriaosylsphingosine level as a primary screening target for Fabry disease in patients with left ventricular hypertrophy","volume":"83","author":"Yamashita","year":"2019","journal-title":"Circ. J."},{"issue":"suppl_1","key":"10.1016\/j.ymgme.2025.109110_bb0255","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy565.2353","article-title":"Plasma lysoGb3 useful as biomarker in screening for Fabry disease in patients with mild left ventricular hypertrophy","volume":"39","author":"Kagimoto","year":"2018","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109110_bb0260","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.025","article-title":"Screening for Fabry disease in Japanese patients with young-onset stroke by measuring \u03b1-galactosidase A and globotriaosylsphingosine","volume":"27","author":"Kinoshita","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"1_suppl","key":"10.1016\/j.ymgme.2025.109110_bb0265","first-page":"96","article-title":"Frequency of Fabry disease and risk factors of young adult stroke in Japan","volume":"4","author":"Kono","year":"2019","journal-title":"Eur. Stroke J."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109110_bb0270","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cge.13936","article-title":"Accuracy diagnosis improvement of Fabry disease from dried blood spots: enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing","volume":"99","author":"Delarosa-Rodr\u00edguez","year":"2021","journal-title":"Clin. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109110_bb0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2019.10.031","article-title":"\u0391-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females","volume":"501","author":"Baydakova","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109110_bb0285","first-page":"2726","article-title":"Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients","volume":"1865","author":"Doykov","year":"2019","journal-title":"Biochim"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0290","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109110_bb0295","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"Muntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109110_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2022.08.003","article-title":"Agalsidase-\u03b2 should be proposed as first line therapy in classic male Fabry patients with undetectable \u03b1-galactosidase A activity","volume":"137","author":"Nowak","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109110_bb0305","article-title":"Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy","volume":"26","author":"Dutra-Clarke","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0315","first-page":"1683","article-title":"Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta","volume":"11","author":"Limgala","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0320","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat\u2014outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109110_bb0325","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy\u2014new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109110_bb0330","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109110_bb0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","article-title":"Treatment switch in Fabry disease- a matter of dose?","volume":"58","author":"Lenders","year":"2021","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2025.109110_bb0340","first-page":"5","article-title":"Response of patients with Fabry disease with the amenable GLA mutation p.n215 s to treatment with migalastat","author":"Feldt-Rasmussen","year":"2017","journal-title":"J. Inborn Errors Metab. Screen."},{"issue":"37","key":"10.1016\/j.ymgme.2025.109110_bb0345","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030345","article-title":"A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease","volume":"101","author":"Hwang","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0350","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jimd.12052","article-title":"Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease","volume":"42","author":"Hennermann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0355","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0360","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","article-title":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies","volume":"130","author":"Nakamura","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0365","first-page":"40","article-title":"Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study","volume":"146","author":"West","year":"2022","journal-title":"Nephron"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0370","first-page":"i107","article-title":"A subgroup analysis of female patients in a phase 3 open-label study to assess the safety and efficacy of pegunigalsidase alfa in patients with Fabry disease previously treated with agalsidase alfa","volume":"36","author":"Hughes","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0375","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0380","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.gim.2022.01.184","article-title":"eP148: long-term safety and efficacy of pegunigalsidase alfa: a multicenter extension study in adult patients with Fabry disease","volume":"24","author":"Gonzalez","year":"2022","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0385","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10157-019-01810-w","article-title":"Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study","volume":"24","author":"Narita","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0390","first-page":"259","article-title":"Lyso-Gb3 does not correlate with clinical measures in patients treated for Fabry disease","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0395","article-title":"Clinical outcomes with migalastat in patients with fabry disease basedondegreeof renal impairment: results from phase 3 trials","volume":"33","author":"Torra","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"suppl_1","key":"10.1016\/j.ymgme.2025.109110_bb0400","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy565.2356","article-title":"Cardiac magnetic resonance imaging in Fabry cardiomyopathy","volume":"39","author":"Moiseev","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2025.109110_bb0405","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fcvm.2018.00108","article-title":"Serum biomarkers of endothelial dysfunction in Fabry associated cardiomyopathy","volume":"5","author":"Loso","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"16","key":"10.1016\/j.ymgme.2025.109110_bb0415","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.3390\/jcm10163734","article-title":"Value of left ventricular feature tracking strain analysis for detection of early cardiac involvement in Fabry disease (FD)","volume":"10","author":"Roller","year":"2021","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109110_bb0420","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/a-0836-2723","article-title":"Assessment of cardiac involvement in Fabry disease (FD) with native T1 mapping","volume":"191","author":"Roller","year":"2019","journal-title":"Rofo"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2025.109110_bb0425","article-title":"Cardiac tissue characterization with t1 and t2 mapping in Anderson fabry patients: new pathophysiological concepts and early cardiac involvement","volume":"41","author":"Zanoni","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0430","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0435","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ymgme.2019.12.010","article-title":"FAbry STabilization indEX (FASTEX): clinical evaluation of disease progression in Fabry patients","volume":"129","author":"Lenders","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109110_bb0440","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.ymgme.2012.11.275","article-title":"Evaluation of urinary biomarkers in patients with Fabry disease","volume":"108","author":"Young","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109110_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109110_bb0450","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2215\/CJN.0000000000000239","article-title":"Early risk stratification for natural disease course in Fabry patients using plasma globotriaosylsphingosine levels","volume":"18","author":"van der Veen","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"17","key":"10.1016\/j.ymgme.2025.109110_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176114","article-title":"Diurnal variation of urinary Fabry disease biomarkers during enzyme replacement therapy cycles","volume":"21","author":"Boutin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109110_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.117851","article-title":"Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients","volume":"556","author":"Ouyang","year":"2024","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0465","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109110_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100968","article-title":"Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease","volume":"25","author":"Hughes","year":"2023","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109110_bb0475","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","article-title":"Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study","volume":"18","author":"Linhart","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109110_bb0480","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmg-2023-109445","article-title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III balance study","volume":"61","author":"Wallace","year":"2024","journal-title":"J. Med. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109110_bb0485","first-page":"24","article-title":"Plasma globotriaosylsphingosine (lysoGb3) correlates strongly with disease severity in untreated Fabry disease patients: a tool to aid clinical decision making","volume":"146","author":"van der Veen","year":"2022","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109110_bb0490","first-page":"179","article-title":"Relationships between cardiac myocyte structural parameters, left ventricular mass index, plasma lyso-GL3 and age in patients with cardiac variant fabry disease","volume":"136","author":"Chang","year":"2017","journal-title":"Nephron"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:24:25Z","timestamp":1752575065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1096719225001015"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109110","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Pharmaceuticals International AG. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109110"}}